Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $400.63 million. The enterprise value is $219.22 million.

Market Cap	400.63M
Enterprise Value	219.22M

Important Dates

The next estimated earnings date is Wednesday, May 15, 2024, after market close.

Earnings Date	May 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 12.85 million shares outstanding. The number of shares has increased by 1,080.37% in one year.

Shares Outstanding	12.85M
Shares Change (YoY)	+1,080.37%
Shares Change (QoQ)	+67.80%
Owned by Insiders (%)	12.99%
Owned by Institutions (%)	17.07%
Float	2.75M

Valuation Ratios

The trailing PE ratio is 10.64.

PE Ratio	10.64
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.15
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.72, with a Debt / Equity ratio of 0.09.

Current Ratio	8.72
Quick Ratio	n/a
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3,025.42

Financial Efficiency

Return on equity (ROE) is -34.40% and return on invested capital (ROIC) is -27.48%.

Return on Equity (ROE)	-34.40%
Return on Assets (ROA)	-28.80%
Return on Capital (ROIC)	-27.48%
Revenue Per Employee	n/a
Profits Per Employee	-$399,088
Employee Count	91
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +90.06% in the last 52 weeks.

Beta (1Y)	n/a
52-Week Price Change	+90.06%
50-Day Moving Average	37.39
200-Day Moving Average	22.26
Relative Strength Index (RSI)	31.77
Average Volume (30 Days)	141,377

Short Selling Information

The latest short interest is 905,983, so 7.05% of the outstanding shares have been sold short.

Short Interest	905,983
Short Previous Month	393,197
Short % of Shares Out	7.05%
Short % of Float	32.90%
Short Ratio (days to cover)	0.09

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-55.58M
Pretax Income	-36.32M
Net Income	-36.32M
EBITDA	-32.35M
EBIT	-36.31M
Earnings Per Share (EPS)	$2.93

Full Income Statement

Balance Sheet

The company has $197.67 million in cash and $16.26 million in debt, giving a net cash position of $181.41 million or $14.11 per share.

Cash & Cash Equivalents	197.67M
Total Debt	16.26M
Net Cash	181.41M
Net Cash Per Share	$14.11
Equity / Book Value	186.02M
Book Value Per Share	14.47
Working Capital	177.38M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$51.42 million and capital expenditures -$321,000, giving a free cash flow of -$51.74 million.

Operating Cash Flow	-51.42M
Capital Expenditures	-321,000
Free Cash Flow	-51.74M
FCF Per Share	-$105.20

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,080.37%
Shareholder Yield	-1,080.37%
Earnings Yield	-9.07%
FCF Yield	-12.92%

Analyst Forecast

The average price target for Neurogene is $43.00, which is 37.95% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$43.00
Price Target Difference	37.95%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on December 19, 2023. It was a reverse split with a ratio of 1:4.

Last Split Date	Dec 19, 2023
Split Type	Reverse
Split Ratio	1:4

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a